Close Close

Regulation and Compliance > State Regulation

Abuse of pain pills fuels virus’s spread, confounding regulators

Your article was successfully shared with the contacts you provided.

(Bloomberg) — The abuse of a pain pill from Endo International P.L.C. and its generic copies is being blamed for an increase of hepatitis C among drug addicts — an unintended consequence of a regulatory decision meant to cut down on misuse.

See also: Just how sick are exchange plan enrollees?

In 2010, U.S. regulators approved a hard-to-abuse version of Purdue Pharma L.P.’s OxyContin, which for a long time had been a drug of choice for opioid addicts. They didn’t just quit using, though, flocking instead to Endo’s extended-release Opana and its generics. The wide needle they use is also perfect for spreading blood-borne viruses.

In a report published Thursday, the Centers for Disease Control and Prevention (CDC) found a sharp rise in new hepatitis C cases in Kentucky, Tennessee, Virginia and West Virginia. Many of the infected were white, young and used injectable drugs. Co-author Jon Zibbell, a CDC scientist, has blamed the abuse of Opana for the surge of cases in some of the poorest areas of the U.S., though the drug wasn’t specifically mentioned in Thursday’s report.

“Opana is a drug that shouldn’t even be on the market,” Zibbell said at an April conference in Atlanta on prescription drug abuse. In an interview later, he said that while approval decisions are up to the FDA, doctors should consider the effectiveness of drugs whose active ingredient is absorbed by the body at a low rate when taken orally and at a much higher rate when injected.

Opana, in pill form, is approved by regulators for pain severe enough to require daily, long-term opioid treatment when alternative options are inadequate. Addicts frequently crush, cook and inject prescription painkillers, sharing needles and passing infections.

Still committed

Endo created an abuse-resistant form of Opana, its top-selling brand-name drug with sales of almost $200 million last year, and sells only that version now. But the FDA said in 2013 that the abuse-deterrent features weren’t good enough to justify blocking cheaper generic versions that aren’t made with the same kind of barriers to misuse.

“We remain committed to working with the FDA, DEA and other state and federal government and industry organizations to address misuse and abuse of opioids,” Endo said in a statement in response to Zibbell’s remarks.

The rising abuse of the pills has put the FDA in an awkward position — fighting to get legitimate patients access to affordable drugs that are also easy for addicts to tamper with. Excessive painkiller prescriptions, improper drug disposal and lack of education are also contributing to opioid abuse, the FDA said in a statement in response to questions regarding Zibbell’s comments in April.

Regulatory path

“We are working hard to help industry develop better abuse-deterrent formulations,” the FDA said. “The FDA is working with many drugmakers to support advancements in this area and help drugmakers navigate the regulatory path to market as quickly as possible.”

The FDA approved the current version of Opana in 2011, allowing the drug for legitimate users. Endo stopped shipping older versions the following year.

Every new hepatitis C infection carries a steep price. Gilead Sciences Inc.’s drug Harvoni, which can cure the liver disease in eight weeks, costs about $1,000 a day and has taxed state health budgets.

Actavis P.L.C., one of two makers of generic Opana, said it also works with government agencies and other organizations to fight prescription-drug abuse. Mark Donohue, a spokesman for the other generic Opana maker, Impax Laboratories Inc., didn’t respond to a phone message.

Painkiller deluge

The U.S. is in the middle of a prescription painkiller deluge. There were enough of the drugs prescribed in the U.S. in 2010 to medicate every person in the country around the clock for a month. And the number of overdose deaths more than tripled from 1999 to 2008, according to the CDC.

Painkillers were implicated in a recent outbreak of HIV in Indiana’s Scott County, just north of the Kentucky border. Public officials found that of the sudden burst of HIV cases, more than 80 percent also had hepatitis C. Almost all were pain-medicine addicts.

Hepatitis C’s spread had dramatically slowed starting in 1992, when the U.S. began testing donated blood. As a result, about 75 percent of the 3.2 million cases of the virus in the U.S. are in people 50 and older, according to the CDC.

That’s changing. After a decade and a half when new cases declined or were flat, in 2010 infections started to rise again. People who inject prescription pain pills are five times more likely to have hepatitis C than injectors of other drugs, the CDC’s Zibbell said.

Infections soar

New hepatitis C infections more than quadrupled from 2006 to 2012 among people 30 years old and younger in Kentucky, Tennessee, Virginia and West Virginia, according to the study the CDC released Thursday. Of 1,374 cases reported in the four states, 45 percent were among young people.

Treatment admissions for prescription opioid abuse accounted for one-third of admissions in the four states for people under 30. Opioids as a class of drugs, prescription or illegal, include heroin and Vicodin, which is now only available in generic versions.

Since hepatitis C can live for two to three weeks on surfaces, people can pass the virus through other drug paraphernalia, not just needles, Zibbell said.

The abuse-deterrent features of Opana may even help pass the virus. When they prepare the drug, addicts may use more cotton balls as filters, water to cook or injections to get high — all adding up to more opportunities for exposure.

More research

Endo didn’t respond to earlier questions about whether misuse of its abuse-deterrent form of Opana — the only version it now sells — contributed to the spread of the virus. The FDA determined that the new version could still readily be prepared for injection and snorting, the agency said in its statement.

Abuse-deterrent technologies add to the cost of drugs, and some work better than others. For now, the pills remain on the market, and infections caused by their abuse continue.

“We need more research into abuse-deterrent forms of drugs,” Jerome Adams, Indiana’s state health commissioner, said on a call with reporters. “Just because a drug comes in an abuse-deterrent form, it doesn’t automatically make it safe.”


© 2023 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.